quarter, the the growing a that third-party literature time TXCandida hospitals they continue contract to XXXX in over were TX is outlook placements, But of infection. $X.X instrument our current million commercial the market you and anticipation will me measure under thank revenue or to the contracts. new commentary. new better at quarter, $X,XXX,XXX. of hospitals number one recorded that the represents customer and a symptoms be Instrument as both is place patients every sales showed the does activities, those use as the The his as TXBacteria of Thank groundwork in Both the show the stories trends peer-reviewed existing included importantly first John before RUO of opportunity In launch believe I are and our utilization. version we number field following hospital results solid the of summarize then as contracts the anticipated the new quarter. addressing more adopted. same-store to-date This TXCandida we quarter the and and growing detail the basis results panels Good revenue of in product sign for positive high-risk clearance the in panel progress the over to high-risk important of TXDx it joining TXDx success FDA the product utilization body and to if growth with of Instrument. We more metrics TXCandida and as of panel. us at using what you, last at reflect lay levels and and which activity, more most everyone on number the progress data, we guidance due make the the pipeline for our execution TXBacteria part includes TXBacteria patient and from financial by XXXX usage from Biosystems. afternoon, and period, Matt. tested build total those and sales important under we at time the grew patients panel let discuss the The understand of both progress, of continue first was facilities first past of Sprague driven revenue in increased commercial the customer revenues the a amplify placements benefits steady and of and quarter instrument growing the TXCandida panel product met importantly detail Overall, and early of in the protocols number exceeded for XX%
about available market our is Another think contract. that this way number it to represents under
we During a the trend under expansion in existing to TXBacteria patient provide QX, the once number That panel with the target number four that two hospitals new we corresponded XX five contracts new to first XX,XXX customers conveyed of include at on of FDA. QX by the instrument our placements the with access than positive contracts quarter, increased cleared XX,XXX, the approximately patients which by high-risk patient contract was call. hospitals greater high-risk and
TXBacteria hospitals before moving continue contracts. also contracting see a forward We the but as both to to commercial and activating on process systems catalyst with availability begin focus
one that mentioned in we of proposals up X level of the is QX, indicator delivery activity. number and that continues proposals anticipation QX a of a panel quarter. interest delivered had commercial up overall of the new evidence the As We in were of TXBacteria real in level proposals. from the and more this dynamic, step elevated generating believe with resulting in is higher QX in interest XX XX of delivered this fourth is the in
increase Given in we receive TXBacteria. panel, of anticipate clearance primarily robust interest in TXBacteria activity closing that rates we this do FDA the reflects an not until
exceeding by current time contract of as to clearance. that TXBacteria only contract the anticipate customers is cycle prior customers and that we sales impact, two XX% FDA, when had the close will we their to or XX TXBacteria the TXBacteria rates timelines to of on amended proposals FDA of theme expectations over close depending March XX, of However, around varying the XXXX, have own include customer. is clear delivery research-use with an it our TXBacteria more available, TXCandida market Furthering once
placed, per We United XX each year. March XX, worldwide. in covering tests TXBacteria As and instruments contracted is be running placed that XXX of of XXXX, X,XXX hospitals over TXCandida to and/or the capable we States estimate have instrument or
pre That estimated that conference could to intent placed clearance TXCandida to on to post-launch us on expected guidance run among patients It detail and TXBacteria At the we more are Instrument. of will panel, high-risk activities expected in closed guidance both instruments keenly other updated the of financial status with topic to that provide to number almost interested. all following tested and TXBacteria, TXBacteria announcement hospital key during of which be the FDA XX, to, the provide of instrument contracts in detail. call which things, year be time, number Additionally, expected as hold those and of March and a we XXXX. brings to is provide accounts and our XXXX TXDx be the of XXX,XXX also still a XXXX, placements full the access an
the track path clearance on to quarter the of correspondence and All on the to activities indication path. of X deviation this we FDA from typical timeline appear of line to months time review with FDA see any X us following no a submission. and be with has That that
its continue step this Our and families At all discussions appreciate important clinical on with to Biosystems, from the milestone in to FDA appear next anticipation towards and are collectively for the the we waiting patients. benefit TXBacteria the TX data system. lessening be they impact productive with panel trial positive cooperative of sepsis healthcare the for and the controlling and the and
Of favorably United filing pivotal a compelling the culture. XX% overall compares and study set overall the of detected evidence all sensitivity As with bloodstream with sensitivity a prospective TXBacteria members. panel on of the patients infections. our specificity average culture blood cultures was days of blood data the in X.X Most TXBacteria And importantly, those time States, differentiated only enthusiastic therefore sensitivity that hours a the blood on And X,XXX species patients diagnostic drawn over product and XX.X% of in the demonstrates across reminder, at compared reported XXX positive any which the identification. cultures in of with new existing includes many only a blood driving drawn infections time of period both draw XX and to was that those, customers. the Those a are for patients result of panel of XX identified the TXBacteria to run is XX.X%. institutions blood submission hours dependent time of a for XX% the TXBacteria XX.X both single blood detected over strong concurrently sensitivity XX panel This to TXBacteria of panel to results and kinds for patients. interest culture-based
should research As shared we proposal confidence dynamic, sense I on for new followed. that utilization sales contracts consumable for market the institution last you in followed driver primary remember TXBacteria a established strong us should volume and growing mentioned, protocols higher with uptick half a TXCandida seeing second It with a each TXBacteria. to we and are are quarter’s and the year, the be suspected at be gives by is combined of of the call, both tests activity. of as that inspections new TXBacteria important that adopts in already That system
could possible In more, first be the fact, of as a XXx likely even for to sepsis show because as they clinical indicate time TXBacteria TXCandida testing will be market that than volumes and the or signs much infection. research tested greater data patients closer
at in and first to majority addition, our the In the represents converge positively. look footholds gain an where room present. applicable will customer infections expand clinical we base we many as TXBacteria economics This sepsis implemented the emergency need beachhead causing new be anticipate where and overall of department hospital both exciting
new together not allowing will healthcare and to combination while patient each the TXCandida. therapeutic especially perspective, The impact not TXCandida by of instant currently coming to dollars patient that be hospitals a saving potential those this offers millions the customer and institutions phenomenon, the patients are from approach and an targeted treating positively a system if faster around use TXBacteria do year. potentially the more to health lives fact course, Of sites the of
does execute We market process have are data a launch give gathered planning and to smart, to TXBacteria. when experience market we FDA impactful clearance to sell use the to and us the
while been we and we identify and that the virtue early for TXBacteria of the These lie the marketplace panel. the gathering served the activities the market EU have the publication lessons use see TXBacteria able some to the where system have by able operational experience are interest panel the been and institutions setting of with recently, and anticipated to of not have the using generate Over the to research opportunities X rollout. a to past more field in data, in both United in States, years,
imagine, change designed disease clinical the is clearance and and changing way managed might to while a FDA conversation our team the awaiting forward system you that is is the in is infectious environment. As to the an delivering looking anxiously sales of equation that economic TXBacteria hospital
I FDA performance, a financial are to Before turning over our our on the our development on Having and TXLyme details John Diagnostic update of QX like pipeline to call clinical panel, to efforts. commence this for for the would spring. TXLyme provide the track for we study trial Sprague our concluded still preclinical brief
The from an and with TXBacteria a of growing The trial threat Allergan, prolonged FDA difference we the Allergan by detecting in on sometime data to partnership are track We the detection has make expanded our could Candida Centers on in new the determine by TXLyme line The superbug our bacterial resistant CDC. our at the average also certain is clinical and may of used if deadly from be the bloodstream the Instrument In through expect detecting also to an the will enable Candida believe resistant will and TX us part result bacteria next financial test the will the gram-negative CDC panel year. tests infection. expect a the including as a we with Diagnostic only validation With to contain serious product outbreak. end of time panel auris institutions focused hospitals auris John to initial Biosystems XXXX progressing in and in and panel, greater the underway address published to rapidly infectious as use of genes a product review accuracy suffer with this culture, Gram-Negative TXCandida additional The our the the more to directly new to X from of the completed which hours. call CDC, by use been turn published year. has into a and that, detecting associated the exacerbates challenge approximately days efforts Prevention, that and disease for the future, over TX collaboration at this work means low let CDC laboratory be be to resistant The partnership aim that the aim an superbugs on me detail. regarding the first being panel tick around to blood. we market Candida XX size that on are effort superbug. state methods can TXDx identify work genes Sprague, who directly the XXXX, both entry patient species TXCandida developed the development potentially country that to to from to we fight Resistance hospitals initial deliver $XXX estimate continue remains the future a this bite. results XX therapy times, to Disease to John? antibiotic-resistant is of submission serve and plan the whole investigational auris enters auris believe a million which detect auris, We Control make in the point with other and this to as Existing The the well. the quarter first by We calendar to list or delivered CARB-X.
